

Research Article

HLA-C Alleles and Cytomegalovirus Retinitis in Brazilian Patients with AIDS

Tânia Gisela Biberg-Salum ¹, Maria de Lourdes Veronese Rodrigues ²,
Ana Paula Morais Fernandes ³, Neifi Hassan Salum Deghaide ⁴, Jayter Silva de Paula ²,
Erick C. Castelli ⁵, Celso Teixeira Mendes-Junior ⁶, and Eduardo Antonio Donadi^{4,7}

¹Ribeirao Preto Medical School, University of São Paulo, University for Development of Pantanal Region (UNIDERP), São Paulo, SP, Brazil

²Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirao Preto Medical School, University of São Paulo, São Paulo, SP, Brazil

³Department of General and Specialized Nursing, Nursing School of Ribeirao Preto, University of São Paulo, São Paulo, SP, Brazil

⁴Molecular Immunology Laboratory and HLA Hemocentro, Ribeirão Preto Medical School University Hospital, Ribeirão Preto, Brazil

⁵School of Medicine, Department of Pathology and Molecular Genetics and Bioinformatics Laboratory, São Paulo State University, Botucatu, SP, Brazil

⁶Departamento de Química, Laboratório de Pesquisas Forenses e Genômicas, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, 14040-901 Ribeirão Preto, SP, Brazil

⁷Division of Immunology, Department of Internal Medicine, Ribeirao Preto Medical School, University of São Paulo, São Paulo, SP, Brazil

Correspondence should be addressed to Ana Paula Morais Fernandes; anapaula@eerp.usp.br

Received 1 March 2018; Revised 13 June 2018; Accepted 8 July 2018; Published 2 September 2018

Academic Editor: Anna Nowinska

Copyright © 2018 Tânia Gisela Biberg-Salum et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Since cytomegalovirus retinitis (CR) is an important cause of visual impairment among AIDS patients and HLA-C alleles have been associated with AIDS disease outcome, we typed HLA-C locus in patients with AIDS exhibiting or not CR. **Methods.** Three groups of individuals were studied: (i) 49 patients with AIDS and CR (Group I), (ii) 161 patients with AIDS without CR (Group II), and (iii) 202 healthy HIV-negative individuals (Group III). HLA-C typing was performed using commercial kits. **Results.** The HLA-C*07 allele group was underrepresented in AIDS patients with CR ($P = 0.005$) when compared to controls or when compared to AIDS patients without CR ($P = 0.006$). The HLA-C*05 allele group was overrepresented in Group II in comparison to Group III ($P = 0.017$). The frequency of the HLA-C*16 allele group was increased in Group III in comparison to Group II ($P = 0.004$). **Conclusion.** The HLA-C*07 allele group conferred protection against the development of CR in Brazilian AIDS patients, whereas the HLA-C*05 and HLA-C*16 allele groups were associated with AIDS susceptibility or protection, respectively.

1. Introduction

Cytomegalovirus retinitis (CR) is the most common ocular opportunistic infection in patients with AIDS, often leading to blindness [1]; however, among patients who experience immune recovery after antiretroviral treatment (ART), an

important reduction in the incidence of CR has been reported [2]. Despite recent advances in treatment, CR continues to rise challenging diagnostic and therapeutic questions since not all patients respond to ART [3].

Progression to AIDS has been strongly associated with the human leukocyte antigen B (HLA-B) alleles, particularly

*HLA-B*57* and *HLA-B*27* allele groups (protection), and *HLA-B*35* (susceptibility), due to the restricted recognition of HIV epitopes by cytotoxic immune system cells [4]. An increasing body of evidence has pointed out the role of *HLA-C* on HIV-1 disease progression. *HLA-C* gene diversity has an impact on HIV infection, particularly a polymorphism located at the promoter region of the *HLA-C* gene (-35C/T), for which the -35C variant has been associated with low viral load and high *HLA-C* mRNA [5].

We have previously reported that susceptibility to CR was associated with *HLA* alleles associated with rapid progression to AIDS, especially *HLA-B35* [6]. To further understand the impact of *HLA-C* polymorphism on CR development among Brazilian patients with AIDS, we evaluated the *HLA-C* allele polymorphism in patients presenting or not CR.

2. Materials and Methods

2.1. Subjects. An observational case-control study was carried out, using DNA samples obtained from patients with AIDS and from healthy individuals, stored in a DNA Sample Bank (Banco de Amostras do Núcleo de Pesquisa em Imunogenética (BANPI)), approved by the local Ethics Committee #7581/2007). All the 210 patients with AIDS were regularly registered at the Brazilian Ministry of Health and were followed up at the University Hospital of the Ribeirão Preto Medical School, the officially recognized hospital to follow-up these patients.

Group I consisted of DNA samples from 49 patients with AIDS presenting CR (38 men aged 21–77 years, median = 35 years), collected regardless of the evolutionary phase or the antiviral treatment of retinochoroiditis. CR was diagnosed by at least two experienced observers, and concordance between them was considered to be a *sine qua non* condition for patient inclusion. Clinical evaluation was performed by indirect binocular ophthalmoscopy, using a Heine Omega 100® ophthalmoscope (Herrsching, Germany), and a 20 diopter Nikon® lens (Melville, USA) under mydriasis produced by the local use of 1% tropicamide (Mydriacyl®, Alcon, São Paulo, Brazil). The CD4⁺ cell count ranged from 1 to 368 cells/mm³ (median = 31), and the viral load ranged from 400 to 8,500,000 copies/mL (median = 85,000). Only 19 (43.2%) of these patients were on antiretroviral therapy. The time since the diagnosis of AIDS ranged from 1–105 months (median = 22 months), and the number of systemic opportunistic infections preceding CR ranged from 0–6 (median = 3). The most frequent infections included candidiasis, neurotoxoplasmosis, pneumocystosis, and neurocryptococcosis.

Group II consisted of DNA samples obtained from 161 patients with AIDS (102 men aged 21–62 years, median = 37 years), randomly selected after performing the ophthalmologic examination excluding the presence of CR and exhibiting no changes of the choroid and retina or any other doubtful retinal diagnosis. The CD4⁺ cell count ranged from 4 to 1164 cells/mm³ (median = 588), and the viral load ranged from 80 to 2,000,000 copies/mL (median = 85,000). Time since the diagnosis of AIDS ranged from 1–108

months (median = 20 months), and these patients experienced 0–8 systemic previous opportunistic infections (median = 2), the most frequent being candidiasis, neurotoxoplasmosis, tuberculosis, and neurocryptococcosis.

Group III consisted of DNA samples from 202 healthy individuals (146 men aged 18–59 years, median = 33 years), exhibiting negative serology for HIV-1.

2.2. *HLA-C* Typing. Patient DNA was obtained from peripheral venous blood collected during the patient follow-up at Unit for the Treatment of Infectious Diseases (UETDI), and healthy control DNA was obtained from bone marrow donors.

HLA-C typing was carried at the Laboratory of Molecular Immunology of HCFMRP-USP, using a commercial kit (Micro SSP DNA Typing Tray, One Lambda, Canoga Park, CA).

2.3. Statistical Analyses. Intergroup differences were determined by the two-tailed Fisher exact test, with calculation of the odds ratio (OR) and 95% confidence interval (95% CI). The level of significance was set at $P \leq 0.05$ in all analyses. In addition, the etiologic fraction (EF) was calculated to determine how much each allele, genotype, or haplotype contributed to susceptibility to CR. The preventive fraction (PF), which estimates how much these same three factors contribute to protection against CR, was also calculated.

3. Results

The *HLA-C*07* allele group was underrepresented in Group I compared to Group II (OR: 0.4233, 95% CI: 0.2246–0.9782, $P = 0.006$), yielding a PF of 0.1531 (Table 1).

When the *HLA-C* allele frequencies were compared between Groups I and III, an underrepresentation of the *HLA-C*07* allele group was also observed for Group I (OR: 0.4192, 95% CI: 0.2246–0.7822, $P = 0.005$), conferring a PF of 0.1553 (Table 2).

The *HLA-C*05* allele group was overrepresented in Group II in comparison to Group III (OR: 2.2045, 95% CI: 1.1665–4.1665, $P = 0.017$), conferring an EF of 0.0455. The frequency of the *HLA-C*16* allele group was increased in Group III in comparison to Group II (OR: 0.3580, 95% CI: 0.1737–0.7380, $P = 0.004$), exhibiting a PF of 0.0524 (Table 3).

4. Discussion

It has been recognized that CR is a condition leading to reduced visual acuity and blindness in patients with AIDS patients; however, with the advent of the more effective antiretroviral therapy, a reduction in the frequency and in the severity of CR has been observed. Notwithstanding, in less favored regions, due to the lack of treatment or incorrect use of medications, or even in more privileged regions due to immunosuppression for organ transplantation, CR continues to deserve special attention.

TABLE 1: HLA-C allele frequencies compared between Groups I (patients with AIDS and CR) and II (patients with AIDS without CR).

Allele	Group I (%)	N	Group II (%)	N	OR	Preventive fraction	P value
HLA-C*01	5.10	5	1.55	5			
HLA-C*02	5.10	5	3.10	10			
HLA-C*03	9.18	9	10.24	33			
HLA-C*04	18.36	18	16.45	53			
HLA-C*05	6.12	6	8.07	26			
HLA-C*06	8.16	8	6.52	21			
HLA-C*07	13.30	13	22.67	73	0.4233	0.1531	0.0063
HLA-C*08	2.04	2	3.10	10			
HLA-C*10	0	0	0.31	1			
HLA-C*12	6.12	6	5.27	17			
HLA-C*13	0	0	0.31	1			
HLA-C*14	0	0	1.86	6			
HLA-C*15	5.1	5	3.41	11			
HLA-C*16	7.14	77	3.10	10			
HLA-C*17	5.1	5	3.41	11			
HLA-C*18	0.0	0	1.55	5			

HLA-C = major histocompatibility complex, class I, C; OR = odds ratio.

TABLE 2: HLA-C allele frequencies compared between Groups I (patients with AIDS and CR) and III (healthy HIV-negative individuals).

Allele	Group I (%)	Group III (%)	N	OR	Preventive fraction	P value
HLA-C*01	5.1	1.73	7			
HLA-C*02	5.1	5.70	23			
HLA-C*03	11.2	6.93	28			
HLA-C*04	22.4	15.33	62			
HLA-C*05	7.1	3.96	16			
HLA-C*06	9.2	9.90	40			
HLA-C*07	13.3	26.73	106	0.4192	0.1553	0.0054
HLA-C*08	2.0	5.70	23			
HLA-C*10	0.0	0.0	0			
HLA-C*12	6.1	6.43	26			
HLA-C*13	0.0	0.0	0			
HLA-C*14	0.0	2.22	9			
HLA-C*15	6.1	3.48	14			
HLA-C*16	7.1	8.17	33			
HLA-C*17	5.1	2.97	13			
HLA-C*18	0.0	0.74	4			

HLA-C = major histocompatibility complex, class I, C; OR = odds ratio.

TABLE 3: HLA-C allele frequencies compared between Groups II (patients with AIDS without CR) and III (healthy HIV-negative individuals).

Allele	Group II (%)	Group III (%)	Etiologic fraction	OR	Preventive fraction	P value
HLA-C*01	1.5	1.7				
HLA-C*02	3.4	5.7				
HLA-C*03	10.8	6.9				
HLA-C*04	17.6	15.3				
HLA-C*05	8.3	4.0	0.0455	2.2045		0.0169
HLA-C*06	7.7	9.9				
HLA-C*07	26.5	26.7				
HLA-C*08	3.4	5.7				
HLA-C*10	0.3	0.0				
HLA-C*12	5.9	6.4				
HLA-C*13	0.3	0.0				
HLA-C*14	1.9	2.2				
HLA-C*15	3.7	3.5				
HLA-C*16	3.1	8.2		0.3580	0.0524	0.0041
HLA-C*17	4.0	3.0				
HLA-C*18	1.5	0.7				

HLA-C = major histocompatibility complex, class I, C; OR = odds ratio.

In the present study, the *HLA-C*07* allele group was underrepresented in AIDS patients with CR, when compared to patients with AIDS without CR and when compared to healthy controls, indicating that the allele group is a protective factor against CR development. Considering that CD4 cell counts observed for patients with AIDS exhibiting CR (1 to 368 cells/mm³, median = 31) were very different from patients with AIDS without CR (4–1164 cells/mm³, median = 588), one may argue that CD4 cell count could be a confounding variable. To circumvent this problem, we compared patients with CR with those without CR, stratified according to the CD4 cell counts, that is, (i) patients with AIDS without CR (exhibiting CD4 ≤ 800 cells/mm³; 4 to 778 cells/mm³, median = 215) versus patients with AIDS and CR (exhibiting CD4 ≤ 368 cells/mm³; 1 to 368 cells/mm³, median = 31) and (ii) patients with AIDS without CR (exhibiting CD4 ≤ 100 cells/mm³; 4 to 99 cells/mm³, median = 49) versus patients with AIDS and CR (exhibiting CD4 ≤ 100 cells/mm³; 1 to 90 cells/mm³, median = 29). The first comparison revealed that the *HLA-C*07* allele group was overrepresented in patients with AIDS without CR ($P = 0.0163$), and the second comparison showed that the *HLA-C*07* allele group was also overrepresented in patients with AIDS without CR ($P = 0.0298$), indicating that the number of CD4 cells counts did not bias the results, and the *HLA-C*07* allele group did protect against CR development in patients with AIDS.

HLA-C alleles have been associated with protection against AIDS development, particularly for patients exhibiting the -35C allele upstream of the *HLA-C* gene, which has been reported to be associated with high cellular expression of *HLA-C* molecules and protection against HIV [7, 8]. Notably, many alleles of the *HLA-C*07* group have been associated with the -35T allele that contributes to low *HLA-C* expression and relatively high risk of disease progression [9]. Then, according to the -35CT dimorphism hypothesis, one should expect that an increased frequency of *HLA-C*07* alleles is associated with the -35T upstream allele, a fact that was not observed in the present study. Although the -35CT hypothesis is very attractive to explain AIDS outcome due to the immune modulatory role of the *HLA-C* molecule, the complete structure of the *HLA-C* gene (regulatory and coding regions) has not been completely studied. Further studies encompassing larger groups of patients with AIDS exhibiting CR as well as the study of the complete *HLA-C* gene could unravel the role of the gene in the susceptibility to CR. Besides the association with CR, the frequency of the *HLA-C*05* allele group was increased in patients with AIDS, irrespective of the presence or not of CR, indicating that this allele group is associated with AIDS susceptibility. On the contrary, patients with AIDS exhibited a reduced frequency of the *HLA-C*16* allele group, indicating a protective factor against the AIDS development.

HLA molecules have a relevant role on the control of HIV infection. Classic examples are the association of *HLA-B*57* and *HLA-B*35* with a slower or faster progression of the disease, respectively [10]. Regarding the *HLA-C* molecules, Silva et al. [11] reported that the *HLA-B*04*, *-B*57*, and *-C*18* alleles were associated with a low viral load in

HIV-infected Brazilian patients. The present results expand the knowledge about the impact of *HLA-C* alleles on CR susceptibility; however, the major limitation of this cross-sectional study is the number of patients with AIDS exhibiting CR, a condition that has been drastically decreased due to the availability of ART.

5. Conclusion

The *HLA-C*07* allele conferred protection against the development of CR in Brazilian patients with AIDS, whereas *HLA-C*05* and *HLA-C*16* allele groups were associated with susceptibility/protection against AIDS development. Considering that the etiologic and preventive fractions conferred by these alleles were low, one may assume that many other genes are implicated on disease development.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors would like to thank Maria Cecilia Onofre for the collaboration in the organization of the manuscript. They would also like to thank Foundation for Support of Teaching, Research and Assistance (FAEPA) for article processing charges.

References

- [1] G. Huang, Q. Jiang, M. Li, Y. Lu, and Z. Wang, "Retrospective study of cytomegalovirus retinitis complicated with acquired immunodeficiency syndrome," *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 6, pp. 9537–9542, 2015.
- [2] D. A. Jabs, A. Ahuja, M. L. Van Natta, A. T. Lyon, S. Yeh, and R. Danis, "Long-term outcomes of cytomegalovirus retinitis in the era of modern antiretroviral therapy: results from a United States Cohort," *Ophthalmology*, vol. 122, no. 7, pp. 1452–1463, 2015.
- [3] A. Timperley, H. Taha, and S. Das, "Management of cytomegalovirus retinitis in HIV infection in the era of highly active antiretroviral therapy," *International Journal of STD & AIDS*, vol. 26, no. 10, pp. 757–758, 2015.
- [4] M. Carrington and S. J. O'Brien, "The influence of *HLA* Genotype on AIDS," *Annual Review of Medicine*, vol. 54, no. 1, pp. 535–551, 2003.
- [5] M. Carrington, A. A. Bashirova, and P. J. McLaren, "On stand by: host genetics of HIV control," *AIDS*, vol. 27, no. 18, pp. 2831–2839, 2013.
- [6] A. P. Fernandes, M. A. G. Gonçalves, R. B. Zavarella, J. F. C. Figueiredo, E. A. Donadi, and M. L. V. Rodrigues, "HLA markers associated with progression to AIDS are also associated with susceptibility to cytomegalovirus retinitis," *AIDS*, vol. 17, no. 14, pp. 2133–2136, 2003.

- [7] E. Raymond, V. Tricottet, D. Samuel, M. Reynès, H. Bismuth, and J. L. Misset, "Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation," *Cancer*, vol. 76, no. 8, pp. 1344–1351, 1995.
- [8] R. Thomas, R. Apps, Y. Qi et al., "HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C," *Nature Genetics*, vol. 41, no. 12, pp. 1290–1294, 2009.
- [9] T. W. Corrah, N. Goonetilleke, J. Kopycinski et al., "Reappraisal of the relationship between the HIV-1-protective single-nucleotide polymorphism 35 kilobases upstream of the HLA-C gene and surface HLA-C expression," *Journal of Virology*, vol. 85, no. 7, pp. 3367–3374, 2011.
- [10] K. D. Squires, M. Monajemi, C. F. Woodworth, M. D. Grant, and M. Larijani, "Impact of APOBEC mutations on CD8+ T cell recognition of HIV epitopes varies depending on the restricting HLA," *Journal of Acquired Immune Deficiency Syndromes*, vol. 70, no. 2, pp. 172–178, 2015.
- [11] E. M. Silva, A. X. Acosta, E. J. Santos et al., "HLA-Bw4-B*57 and Cw*18 alleles are associated with plasma viral load modulation in HIV-1 infected individuals in Salvador, Brazil," *Brazilian Journal of Infectious Diseases*, vol. 14, no. 5, pp. 468–475, 2010.